CN Patent

CN101541310A — 缬更昔洛韦的粉末制剂

Assigned to Koplar Pharmaceutical Pharmaceutical Co ltd · Expires 2009-09-23 · 17y expired

What this patent protects

本发明提供了在水中配制后口服施用的缬更昔洛韦盐酸盐新的固体药物剂型。这些新的药物剂型用于治疗或控制病毒，诸如单纯疱疹病毒或巨细胞病毒。

USPTO Abstract

本发明提供了在水中配制后口服施用的缬更昔洛韦盐酸盐新的固体药物剂型。这些新的药物剂型用于治疗或控制病毒，诸如单纯疱疹病毒或巨细胞病毒。

Drugs covered by this patent

valganciclovir-hydrochloride (VALGANCICLOVIR HYDROCHLORIDE)

Patent Metadata

Patent number: CN101541310A
Jurisdiction: CN
Classification: —
Expires: 2009-09-23
Drug substance claim: No
Drug product claim: No
Assignee: Koplar Pharmaceutical Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.